Vaccitech's Series A Round

Vaccitech raised a round of funding on January 16, 2018.

Vaccitech is developing a universal flu vaccine, based on inducing cellular immune responses using non-replicating viral vectors for treatment or prophylaxis against diseases at various stages. As wel…

Articles about Vaccitech's Series A Round: